Oral vs Intravenous Antibiotics for Fracture-Related Infections
JAMA Surgery · 01.03.2025 · 160 (3) · 276
DOI: 10.1001/jamasurg.2024.6439 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Surgery, erschienen am 01.03.2025. Verfasst von Major Extremity Trauma Research Consortium (METRC) und 59 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Fracture Fixation, Fractures, Bone, Surgical Wound Infection. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Fracture-related infection (FRI) is a serious complication following fracture fixation surgery. Current treatment of FRIs entails debridement and 6 weeks of intravenous (IV) antibiotics. Lab data and retrospective clinical studies support use of oral antibiotics, which are less expensive and may have fewer complications than IV antibiotics.
Objective
To evaluate the effectiveness of treatment of FRI with oral vs IV antibiotics. Design, Setting, and Participants The POvIV multicenter, prospective randomized clinical trial was conducted across 24 trauma centers in the US among patients aged 18 to 84 years who had fracture repair or arthrodesis with fixation with implants and developed an FRI without radiographic evidence of osteomyelitis. Patients were enrolled between March 2013 and September 2018 and followed up for 12 months after hospitalization for treatment of their FRI.
Intervention
Oral vs IV antibiotics following FRI. Main Outcomes and Measures The primary outcome was number of surgical interventions, and the primary hypothesis was noninferiority of oral vs IV antibiotics with respect to the number of study injury–related surgical interventions by 1 year. Unadjusted modified intent-to-treat (mITT) and adjusted per-protocol (PP) analyses were prespecified. A post hoc adjusted mITT analysis was conducted to resolve discrepancies between the results of the prespecified mITT and PP analyses. Recurrence of a deep surgical site infection was a key secondary outcome.
Results
Among 233 total patients, mean (SD) age was 46.0 (13.9) years, and 53 patients were female (22.7%). The mean number of surgical interventions within 1 year was 1.3 and 1.1 for the oral and IV groups, respectively. The upper bound of the 95% confidence interval of the mean difference with unadjusted mITT analysis was 0.59, which was lower than the prespecified noninferiority margin of 0.67, indicating noninferiority of oral to IV antibiotics. Adjusted PP analysis did not support noninferiority of the number of reoperations. A post hoc adjusted mITT analysis also showed noninferiority. The treatment effects estimates for the key secondary outcome of reinfection showed a similar pattern as those for the primary outcome. Conclusions and Relevance In this prospective randomized clinical trial, oral antibiotic treatment was noninferior to IV treatment with respect to the primary outcome of number of surgical interventions based on mITT analysis. However, there is some uncertainty in these findings based on preplanned and post hoc secondary analyses. A similar pattern of treatment effect estimates was observed for the secondary outcome of recurrence of infection. Trial Registration ClinicalTrials.gov Identifier: NCT01714596
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vanderbilt University Medical Center, Nashville, Tennessee.
- R Adams Cowley Shock Trauma Center at the University of Maryland School of Medicine, Baltimore.
- The University of California, San Francisco.
- Boston Medical Center, Boston, Massachusetts.
- Brooke Army Medical Center, Fort Sam Houston, Texas.
- Center for Orthopedic Research and Education, Phoenix, Arizona.
Zitieren
APA
Major Extremity Trauma Research Consortium (METRC), Obremskey, W. T., O'Toole, R. V., Morshed, S., Tornetta, P., Murray, C. K., Jones, C. B., Scharfstein, D. O., Taylor, T. J., Carlini, A. R., DeSanto, J. M., Castillo, R. C., Bosse, M. J., Karunakar, M. A., Seymour, R. B., Sims, S. H., Weinrib, D. A., Churchill, C., Carroll, E. A., …, & Archer, K. R. (2025). Oral vs Intravenous Antibiotics for Fracture-Related Infections. JAMA Surgery, 160(3), 276. https://doi.org/10.1001/jamasurg.2024.6439
Vancouver
Major Extremity Trauma Research Consortium (METRC), Obremskey WT, O'Toole RV, Morshed S, Tornetta P, Murray CK, et al. Oral vs Intravenous Antibiotics for Fracture-Related Infections. JAMA Surgery. 2025;160(3):276. doi:10.1001/jamasurg.2024.6439
BibTeX
@article{MajorExtremityTraumaResearchConsortiumMETRC2025,
author = {Major Extremity Trauma Research Consortium (METRC), Major Extremity Trauma Research Consortium (METRC) and Obremskey, William T and O'Toole, Robert V and Morshed, Saam and Tornetta, Paul and Murray, Clinton K and Jones, Clifford B and Scharfstein, Daniel O and Taylor, Tara J and Carlini, Anthony R and DeSanto, Jennifer M and Castillo, Renan C and Bosse, Michael J and Karunakar, Madhav A and Seymour, Rachel B and Sims, Stephen H and Weinrib, David A and Churchill, Christine and Carroll, Eben A and Pilson, Holly T and Goodman, James Brett and Holden, Martha B and Miller, Anna N and Sietsema, Debra L and Stahel, Philip F and Mir, Hassan and Schmidt, Andrew H and Westberg, Jerald R and Mullis, Brian and Shively, Karl D and Hymes, Robert A and Konda, Sanjit R and Vallier, Heather A and Breslin, Mary Alice and Smith, Christopher S and Crickard, Colin V and Egol, Kenneth A and Reid, J Spence and Baker, Mitch and Eglseder, W Andrew and LeBrun, Christopher and Manson, Theodore and Mascarenhas, Daniel C and Nascone, Jason and Pollak, Andrew N and Schloss, Michael G and Sciadini, Marcus F and Degani, Yasmin and Miclau, Theodore and Weiss, David B and Yarboro, Seth R and McVey, Eric D and Firoozabadi, Reza and Agel, Julie and Whiting, Paul S and Haleem, Ambar and Domes, Christopher and Lang, Gerald J and Kuhn, Gabrielle R and Archer, Kristin R},
title = {Oral vs Intravenous Antibiotics for Fracture-Related Infections},
journal = {JAMA Surgery},
year = {2025},
volume = {160},
number = {3},
pages = {276},
doi = {10.1001/jamasurg.2024.6439}
}
EUVIMED